ViruCure Therapeutics is a biotech company that is developing an oncolytic-virus-based technology platform, NADAV, for the targeted treatment of a wide range of cancers.
ViruCure’s robust NADAV platform has already shown the potential to have significant oncolytic effect on a wide range of cancers including recurrent Glioblastoma Multiforme (GBM) and lung cancer (LC), which are the two initial target indications to be addressed by ViruCure. In a Phase 1/2 clinical trial on terminal recurrent GBM patients, four of twelve patients responded to treatment and one went into complete remission! Studies have also been conducted on metastatic chemo-resistant melanoma in mice and human organ cultures in lung cancer, head and neck, as well as colorectal carcinomas.
NADAV’s oncolytic effect appears to be a result of both direct destruction of the tumor cells (cell death) and activation of a general anti-tumor immune response. This powerful amplification effect is achieved with very low toxicity because NADAV specifically destroys tumor cells and does not attack normal tissues. Furthermore, since NADAV is based on an avian virus (Newcastle Disease Virus (NDV)), it has not exhibited any pathological effects or severe illnesses in humans in over forty years of research.
ViruCure believes that NADAV may serve as a breakthrough treatment modality where conventional cancer therapies have shown poor results. Given its broad applicability, the NADAV platform will generate an evergreen pipeline of anti-cancer candidates, some of which ViruCure will bring to market on its own and others through strategic partnerships.